Clinical Trial Update: A Phase 3 Study of Duvelisib Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing duvelisib to ofatumumab in relapsed/refractory CLL/SLL has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Duvelisib (duvelisib)
• Ofatumumab (ofatumumab)

Snippet

Sponsor: SecuraBio | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2019-01-08